Printer Friendly

ROBERTS PHARMACEUTICAL CARDIOVASCULAR DRUG CLINICAL RESULTS TO BE REPORTED AT AMERICAN COLLEGE OF CARDIOLOGY MEETING

 ROBERTS PHARMACEUTICAL CARDIOVASCULAR DRUG CLINICAL RESULTS TO BE
 REPORTED AT AMERICAN COLLEGE OF CARDIOLOGY MEETING
 EATONTOWN, N.J., Feb. 5 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) today announced the presentation of a study reporting the therapeutic benefit of Amatine(R) (midodrine) scheduled for the annual scientific session of the American College of Cardiology to be held April 12-16.
 Dr. Fetnat Fouad-Terazi will report at the meeting in Dallas that eight patients with the disabling condition of orthostatic hypotension, who had difficulty standing upright because of low blood pressure, were treated with Amatine or a comparative drug ephedrine in a double-blind study at the Cleveland Clinic. When the patients received Amatine, their standing blood pressures were significantly increased, improving their ability to stand upright. Side effects to the drug were mild. There was no improvement with ephedrine. Fouad-Terazi's colleagues in this study were Drs. Masanori Okabe and Hershel Goren.
 In announcing the scheduled presentation, Dr. Robert A. Vukovich, chairman and CEO of Roberts Pharmaceutical Corporation, noted, "There are currently no drugs for orthostatic hypotension approved for use in the United States. However, Amatine has been successfully used in Europe for 10 years. Ephedrine, the drug with which Amatine was compared in the study, has been used in the United States with only limited success."
 Orthostatic hypotension can result from autonomic insufficiency, a defect in the body's systems for regulating blood pressure. Blood pressure is abnormally low when a patient assumes a standing position, and the patient can become dizzy or even faint. Amatine is an alpha- adrenergic agonist that constricts smooth muscles and increases the resistance of peripheral blood vessels to the flow of blood, thus elevating blood pressure.
 Roberts Pharmaceutical Corporation is engaged in the business of acquiring, developing and marketing human pharmaceutical in the United States and abroad. The company is developing late stage pharmaceuticals of the treatment of cancer, respiratory disease, endocrine disorders, pain management, cardiovascular and urologic conditions. Roberts currently markets a line of prescription and non-prescription pharmaceuticals in the United States and abroad.
 -0- 2/5/92
 /CONTACT: Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182/
 (RPCX) CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU:


CK-TS -- NY046 -- 7200 02/05/92 12:43 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 5, 1992
Words:369
Previous Article:IGA PETITIONS NLRB FOR CERTIFICATION
Next Article:PHELPS DODGE CORPORATION DECLARES FIRST QUARTER DIVIDEND
Topics:


Related Articles
/C O R R E C T I O N -- ROBERTS PHARMACEUTICALS/
Alexion C5 Inhibitor Demonstrates Ability to Block Tissue Damage During Myocardial Infarction
SONUS Pharmaceuticals Appoints Dr. John Flaherty as Senior Vice President.
Kos Pharmaceuticals Alliance With DuPont Pharmaceuticals Cleared By The Federal Trade Commission.
ALT-711 Phase IIa Human Data Reveals Potential To Reverse Age-Related Cardiovascular Disease.
August Watanabe, M.D., Elected to Board of Directors Of QuatRx Pharmaceuticals Company.
Dr. Valentin Fuster Joins Vasogen's Scientific Advisory Board.
Dr. Martin B. Leon of the Cardiovascular Research Foundation to Act as Biopure's Chief Medical Director.
Myogen Announces Publication of Ambrisentan Data in Two Scientific Journals.
NUCRYST Pharmaceuticals appoints Dr. David Poorvin to the Board of Directors.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters